Route of administration other than oral for concomitant me­di­cation [Bioanalytics]

posted by Ohlbe – France, 2020-02-05 10:13 (394 d 19:16 ago) – Posting: # 21147
Views: 1,321

Dear Qualityassurance,

» Can anyone suggest me :confused::confused: if it is required to include these medications in concomitant medication experiment if the route of administration is other than oral (e.g. IV, topical, eye drops) during clinical phase?

I would say it depends on the bioavailability of these products when administered by these routes. For IV, no discussion (at least, if there is an active substance - don't bother about saline or glucose). But for a topical administration the answer is likely that there is no point.


Complete thread:

 Admin contact
21,370 posts in 4,463 threads, 1,495 registered users;
online 7 (0 registered, 7 guests [including 2 identified bots]).
Forum time: Saturday 05:30 CET (Europe/Vienna)

If debugging is the process of removing bugs,
then programming must be the process of putting them in.    Edsger W. Dijkstra

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz